Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARFONAD vs INVERSINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Arfonad (trimethaphan camsylate) is a ganglionic blocking agent that competitively inhibits nicotinic acetylcholine receptors at autonomic ganglia, resulting in sympathetic and parasympathetic blockade. This leads to vasodilation and decreased peripheral vascular resistance.
Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors, blocking ganglionic transmission in both sympathetic and parasympathetic ganglia.
Controlled hypotension during surgery,Hypertensive emergencies
Management of moderately severe to severe essential hypertension,Unresponsive hypertension to other agents
Intravenous infusion: 0.5-1 mg/min initially, titrated to desired blood pressure reduction; typical maintenance 1-4 mg/min.
Initial: 2.5 mg orally twice daily; increase by 2.5-5 mg every 2-3 days until blood pressure controlled; usual maintenance: 10-75 mg/day in 2-4 divided doses; max single dose: 25 mg; max daily dose: 200 mg.
Terminal elimination half-life is approximately 1-2 minutes due to rapid hydrolysis by plasma esterases, leading to ultrashort duration.
3-5 hours in patients with normal renal function; may be prolonged in renal impairment (up to 12-24 hours in severe cases).
Primarily metabolized by plasma pseudocholinesterase (butyrylcholinesterase); also undergoes hepatic metabolism.
Primarily hepatic metabolism (unknown specific enzymes); eliminated renally with unchanged drug and metabolites.
Primarily renal excretion of unchanged drug (approximately 30-50%) with the remainder metabolized; minimal biliary/fecal elimination.
Primarily renal (about 90% as unchanged drug), with minor biliary/fecal elimination (<10%).
Approximately 50% bound to plasma proteins, primarily albumin.
~50% bound to plasma proteins (mainly albumin).
Approximately 0.3 L/kg, indicating distribution mainly in extracellular fluid.
Approximately 1 L/kg, indicating extensive extravascular distribution.
Only administered intravenously; oral bioavailability is negligible due to rapid hydrolysis.
Oral: 50-75% (due to first-pass metabolism).
No specific dose adjustment recommended based on GFR; use with caution in severe renal impairment due to potential for accumulation.
GFR 30-60 m L/min: reduce dose by 50%; GFR 10-29 m L/min: reduce dose by 75%; GFR <10 m L/min: avoid use.
No specific Child-Pugh based dose adjustments; caution in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Not recommended in pediatric patients due to lack of safety and efficacy data.
Not recommended for pediatric use due to lack of safety and efficacy data.
Initiate at lower end of dosing range (0.5 mg/min) and titrate slowly due to increased sensitivity to hypotension and reduced metabolic clearance.
Start at 2.5 mg once daily; increase slowly; monitor for orthostatic hypotension and syncope.
None.
None.
May cause profound hypotension; monitor blood pressure closely.,Use with caution in patients with hypovolemia, myocardial ischemia, or cerebrovascular insufficiency.,Can cause histamine release leading to bronchospasm; avoid in patients with asthma.,May cause pupillary dilation and cycloplegia; use caution with glaucoma.,Can inhibit plasma pseudocholinesterase; prolonged effect in patients with atypical pseudocholinesterase.
May cause orthostatic hypotension, syncope, and falls. Use with caution in patients with cerebrovascular insufficiency, renal impairment, or recent myocardial infarction. Discontinue if symptoms of paralytic ileus occur.
Hypersensitivity to trimethaphan or any component,Severe hypotension or shock,Myocardial infarction or coronary insufficiency,Uncompensated heart failure,Asthma or severe chronic obstructive pulmonary disease,Glaucoma (narrow-angle),Pregnancy (category C; may cause fetal harm)
Coronary insufficiency, recent myocardial infarction, pyloric stenosis, glaucoma, uremia, and patients receiving concurrent antihypertensive therapy with ganglionic blocking agents.
No specific food interactions; however, avoid large meals before surgery as general fasting guidelines apply.
Avoid excessive intake of tyramine-rich foods (e.g., aged cheeses, cured meats) as mecamylamine may potentiate pressor effects. Limit alcohol consumption due to additive hypotensive effects. High-sodium foods may counteract antihypertensive effect; follow a low-sodium diet as recommended.
Arfonad (trimethaphan camsylate) is a ganglionic blocker used for controlled hypotension. FDA Pregnancy Category C. Animal studies are inadequate. No well-controlled human studies. Potential for fetal harm due to maternal hypotension and reduced uteroplacental perfusion. First trimester: theoretical risk of teratogenicity due to altered hemodynamics, but no specific malformations reported. Second and third trimesters: risk of fetal hypoxia, bradycardia, and acidosis due to maternal hypotension. Avoid use in pregnancy unless clearly needed.
Category C. First trimester: No adequate human studies; animal studies show embryotoxicity. Second/third trimester: Potential for meconium ileus, neonatal hypotension. Avoid in pregnancy.
No data on excretion in human milk. M/P ratio unknown. Caution: due to potential for ganglionic blockade in infant, consider benefit vs risk. A decision should be made to discontinue nursing or discontinue drug.
Excreted in breast milk. M/P ratio unknown. Discontinue breastfeeding due to potential for serious adverse effects in infant.
Pregnancy may alter pharmacokinetics; however, specific dose adjustments for Arfonad are not established. Use lowest effective dose. Rapid titration with continuous monitoring to achieve desired hypotensive effect while avoiding excessive hypotension and fetal compromise.
No established dosing guidelines for pregnancy; increased clearance suggests need for dose escalation, but contraindicated due to risks.
Arfonad (trimethaphan camsylate) is a ganglionic blocker used for controlled hypotension during surgery. Monitor blood pressure closely as it can cause profound hypotension. Tachyphylaxis develops rapidly. Use with caution in patients with renal impairment, as drug accumulation may occur. Administer via continuous IV infusion, titrating to desired effect. Have vasopressors (e.g., phenylephrine) ready to reverse hypotension. Arfonad can release histamine, so monitor for bronchospasm in asthmatics.
INVERSINE (mecamylamine) is a noncompetitive nicotinic acetylcholine receptor antagonist used primarily for its ganglionic blocking effects in severe hypertension. Due to its narrow therapeutic index and significant side effects including orthostatic hypotension, constipation, and urinary retention, it is rarely used today. Monitor for paralytic ileus and bladder distention. Dosage must be titrated carefully based on standing blood pressure. Contraindicated in patients with coronary insufficiency, pyloric stenosis, or recent myocardial infarction.
You will receive this medication only in the hospital, typically during surgery.,Your blood pressure will be closely monitored throughout the infusion.,Report any difficulty breathing, hives, or palpitations immediately.,This medication may cause blurred vision, dizziness, or dry mouth; avoid sudden position changes.,Do not stop the infusion abruptly; it will be tapered by your healthcare team.
Take this medication exactly as prescribed; do not change dose without consulting your doctor.,Rise slowly from sitting or lying positions to avoid dizziness from low blood pressure.,Report any constipation, difficulty urinating, or blurred vision to your healthcare provider immediately.,Avoid alcohol and other medications that lower blood pressure without medical advice.,Do not drive or operate heavy machinery if you experience dizziness or blurred vision.,Maintain adequate fluid intake unless otherwise directed by your doctor.
No interactions on record
No interactions on record
Common clinical questions about ARFONAD vs INVERSINE, answered by our medical review team.
ARFONAD is a Ganglionic Blocker that works by Arfonad (trimethaphan camsylate) is a ganglionic blocking agent that competitively inhibits nicotinic acetylcholine receptors at autonomic ganglia, resulting in sympathetic and parasympathetic blockade. This leads to vasodilation and decreased peripheral vascular resistance.. INVERSINE is a Ganglionic Blocker Antihypertensive that works by Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors, blocking ganglionic transmission in both sympathetic and parasympathetic ganglia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARFONAD and INVERSINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARFONAD is: Intravenous infusion: 0.5-1 mg/min initially, titrated to desired blood pressure reduction; typical maintenance 1-4 mg/min.. The standard adult dose of INVERSINE is: Initial: 2.5 mg orally twice daily; increase by 2.5-5 mg every 2-3 days until blood pressure controlled; usual maintenance: 10-75 mg/day in 2-4 divided doses; max single dose: 25 mg; max daily dose: 200 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARFONAD and INVERSINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARFONAD is classified as Category C. Arfonad (trimethaphan camsylate) is a ganglionic blocker used for controlled hypotension. FDA Pregnancy Category C. Animal studies are inadequate. No well-controlled human studies.. INVERSINE is classified as Category C. Category C. First trimester: No adequate human studies; animal studies show embryotoxicity. Second/third trimester: Potential for meconium ileus, neonatal hypotension. Avoid in pre. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.